Centers for Mendelian Genomics: A decade of facilitating gene discovery
- PMID: 35148959
- PMCID: PMC9119004
- DOI: 10.1016/j.gim.2021.12.005
Centers for Mendelian Genomics: A decade of facilitating gene discovery
Abstract
Purpose: Mendelian disease genomic research has undergone a massive transformation over the past decade. With increasing availability of exome and genome sequencing, the role of Mendelian research has expanded beyond data collection, sequencing, and analysis to worldwide data sharing and collaboration.
Methods: Over the past 10 years, the National Institutes of Health-supported Centers for Mendelian Genomics (CMGs) have played a major role in this research and clinical evolution.
Results: We highlight the cumulative gene discoveries facilitated by the program, biomedical research leveraged by the approach, and the larger impact on the research community. Beyond generating a list of gene-phenotype relationships and participating in widespread data sharing, the CMGs have created resources, tools, and training for the larger community to foster understanding of genes and genome variation. The CMGs have participated in a wide range of data sharing activities, including deposition of all eligible CMG data into the Analysis, Visualization, and Informatics Lab-space (AnVIL), sharing candidate genes through the Matchmaker Exchange and the CMG website, and sharing variants in Genotypes to Mendelian Phenotypes (Geno2MP) and VariantMatcher.
Conclusion: The work is far from complete; strengthening communication between research and clinical realms, continued development and sharing of knowledge and tools, and improving access to richly characterized data sets are all required to diagnose the remaining molecularly undiagnosed patients.
Keywords: Centers for Mendelian Genomics (CMG); Data sharing; Mendelian conditions; Novel gene-disease discovery; Rare disease tools.
Copyright © 2021 American College of Medical Genetics and Genomics. All rights reserved.
Conflict of interest statement
Conflict of Interest Baylor College of Medicine and Miraca Holdings Inc have formed a joint venture with shared ownership and governance of Baylor Genetics, formerly the Baylor Miraca Genetics Laboratories, which performs clinical ES and chromosomal microarray analysis for genome-wide detection of copy number variants. J.R.L. serves on the Scientific Advisory Board of Baylor Genetics. J.R.L. has stock ownership in 23andMe, is a paid consultant for Regeneron Pharmaceuticals, and is a coinventor on multiple United States and European patents related to molecular diagnostics for inherited neuropathies, eye diseases, and bacterial genomic fingerprinting. H.L.R. receives funding from Illumina to support rare disease gene discovery and diagnosis. Consortium author conflicts of interest are listed in the Supplement. All other authors have no disclosures relevant to the manuscript.
Figures


References
Publication types
MeSH terms
Grants and funding
- UM1 HG008900/HG/NHGRI NIH HHS/United States
- UM1 HG006504/HG/NHGRI NIH HHS/United States
- K23 DK114551/DK/NIDDK NIH HHS/United States
- T32 HG010464/HG/NHGRI NIH HHS/United States
- UM1 HG006542/HG/NHGRI NIH HHS/United States
- R35 NS105078/NS/NINDS NIH HHS/United States
- K08 HG008986/HG/NHGRI NIH HHS/United States
- UM1 HG006493/HG/NHGRI NIH HHS/United States
- U24 HG008956/HG/NHGRI NIH HHS/United States
- U01 HG011758/HG/NHGRI NIH HHS/United States
- P50 HD103538/HD/NICHD NIH HHS/United States
- R01 HG009141/HG/NHGRI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Miscellaneous